Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is a male between 40 and 95 years of age~* Has osteoporosis~* Has anatomy suitable for dual energy x-ray absorptiometry (DXA) scan of the lumbar spine and and hip~* Is ambulatory~Exclusion Criteria:~* Is currently on oral bisphosphonates or other treatment for osteoporosis~* Had previous hip fragility fracture and is a candidate for standard of care therapy~* Has had a fragility fracture (vertebral or non-vertebral fractures indicating reduced bone strength) within 12 months~* Has had more then one previous vertebral fracture~* Has been diagnosed with metabolic bone disorder other than osteoporosis~* Is Vitamin D deficient~* Has a history of renal stones~* Has active parathyroid disease~* Has history of thyroid disease not well controlled by medication~* Is diagnosed with secondary osteoporosis~* Has a daily calcium intake of \<1,200 mg and is unwilling to take study prescribed supplements or increase dietary intake, such that his daily calcium intake is at least 1200 mg~* Has a history of malignancy ≤5 years prior to signing informed consent~* Has been diagnosed with hypogonadism due to causes that affect multiple organ and body systems

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg once weekly (Type: EXPERIMENTAL): Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
- Placebo once weekly (Type: PLACEBO_COMPARATOR): Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).